Currently, the diagnosis of myelofibrosis (MF) centers around the 2016 diagnostic criteria developed by the World Health Organization (WHO), which combine clinical, laboratory, genetic, and histologic assessments.1 Clinical Assessments for MF Diagnosis The primary clinical assessment should confirm palpable splenomegaly, which the WHO lists as 1 of 5 minor criteria for the diagnosis of MF.1…
Myelofibrosis (MF) involves the clonal proliferation of hematopoietic stem cells in the bone marrow, which leads to cytokine release and bone marrow fibrosis. The prognosis or disease course may vary among patients with MF. While some patients remain stable for long periods with minimal interruptions due to the disease, others may experience rapid disease progression…
Myelofibrosis (MF), one of the 3 classic myeloproliferative neoplasms, is characterized by an accumulation of fibrotic scar tissue in the bone marrow, which interferes with the normal production of blood cells such as erythrocytes, platelets, and leukocytes. A specific cause of primary myelofibrosis has yet to be discovered, but factors such as genetic mutations have…
Myelofibrosis (MF) is a myeloproliferative neoplastic disorder. MF is characterized by bone marrow fibrosis, splenomegaly and/or hepatomegaly, and constitutional symptoms.1 Incidence and Prevalence of Myelofibrosis Based on a meta-analysis of 34 highly heterogeneous studies conducted across the globe, the worldwide annual incidence rate of MF is reported to be around 0.47 cases per 100,000 people.2…
Myelofibrosis (MF) is a rare disorder in which bone marrow scarring due to the production of excess fibrous tissue interferes with the normal production of blood cells. MF is characterized by a range of symptoms, including anemia, easy bleeding and bruising, fatigue, bone or joint pain, and splenomegaly.1,2 The symptoms and progression of the disease…
Gamida Cell is gearing up to begin sales of omidubicel from Israel to US hospitals for use in stem cell transplants, pending FDA approval of the therapy.
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Abigail Jenkins, president and CEO of Gamida Cell, on the company’s development of omidubicel as an alternative to umbilical cord blood in stem cell transplants for myelofibrosis and other diseases. Read the full story here: Omidubicel Shows Promise as Replacement for Umbilical Cord Blood in Stem…
